# Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection

> **NCT01055847** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 105 (actual)

## Conditions studied

- Cystic Fibrosis
- CF
- Lung Infection
- Pseudomonas Aeruginosa

## Interventions

- **DRUG:** Aztreonam for Inhalation (AI)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01055847
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-08
- **Final completion:** 2004-09
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2010-01-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01055847

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01055847, "Aztreonam for Inhalation (AI) in Patients With Cystic Fibrosis & P. Aeruginosa Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01055847. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*